TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC).

Authors :: Powles, Thomas
Necchi, Andrea
Duran, Ignacio
Loriot, Yohann
Ramamurthy, Chethan
Recio-Boiles, Alejandro
Sweis, Randy F.
Bedke, Jens
Tonelli, Julia
Sierecki, Mitch
Grivas, Petros
Barthelemy, Philippe
Source :: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, pTPS598-TPS598, 1p
Publication Year :: 2023

Full Text Access

Tools